Gyre Therapeutics, Inc., a cutting-edge, commercial-stage biopharmaceutical business committed to developing fibrosis-first treatments across organ systems impacted by chronic illnesses, is receiving advice from Gibson Dunn on its purchase of Cullgen Inc.